Threshold Begins Dosing With TH-302 In Relapsed Multiple Myeloma Trial

(RTTNews) - Threshold Pharmaceuticals, Inc. (THLD) Wednesday said it has begun dosing in the final stage of an ongoing Phase 1/2 trial of its investigational drug, TH-302, in combination with the proteasome inhibitor bortezomib and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma, a cancer of the bone marrow.

The Phase 1/2 study is for evaluating the safety and tolerability, and for determining dose-limiting toxicities and the maximum-tolerated dose of TH-302, in patients with refractory multiple myeloma. In the final stage, an initial dose of TH-302 of 240 mg/m2 will be administered twice weekly for the first two weeks of a three-week treatment cycle. The dose of TH-302 will be escalated in cohorts of 3-6 patients, while the dose of bortezomib will remain fixed at 1.3 mg/m2.

"Data seen thus far are encouraging using the combination of TH-302 and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma," said Irene Ghobrial, Principal Investigator of the Phase 1/2 trial.